康宁克通-A局部注射治疗瘢痕增生175例

从1987年至1996年6月，我院采用康宁克通-A瘢痕内注射治疗增生性瘢痕及瘢痕疙瘩175例，取得满意疗效，报道如下。1．一般资料：175例中，头面部外伤性增生性瘢痕85例，两部、颈部手术切口瘢痕64例，耳垂、胸骨及三角肌区瘢痕疙瘩26例。年龄最小2岁，最大62岁。男81例，女94例。瘢痕面积从0．5cm×1cm至3cm×4cm不等。2．治疗方法：局部用2．5％碘可、75％酒精消毒2次。sml注射器4～5号外头如吸康宁克通Iml（40mg），面积较大需多点注射者可加l～Zml普鲁卡因。注射点数视癫痕面积大小从1点至5点不等。药液注射拥痕内使搬痕颜色变得苍白。注…     

结直肠癌病检淋巴结数目与TNM分期及预后的关系

目的 探讨病检淋巴结数目与结直肠癌分期及预后的关系.方法 将567例结直肠癌患者根据术后病检的淋巴结数目分为3个组:≤6枚、7～11枚、≥12枚组,比较各组5年生存率的差别.TNM分期(Ⅰ～Ⅳ期)分别以病检淋巴结数目分为<12枚和≥12枚两组,比较各分期中两组的5年生存率的差别,分析预后相关因素.5年生存率的比较采用Kaplan-Meier法并经Log-rank检验,预后多因素分析采用Cox比例风险模型.结果 567例平均病检淋巴结数目为(16.75±9.88)枚,病检淋巴结数目分别为≤6枚,7～11枚,≥12枚时,结直肠癌5年生存率各为32.3%(21/65),43.8%(53/121),57.7%(220/381),单因素分析表明,病检淋巴结数目≥12枚的结直肠癌5年生存率明显高于其他两组(≤6枚,7～11枚)(P<0.05).<12枚、≥12枚淋巴结两组在Ⅰ期或Ⅳ期的结直肠癌5年生存率无明显差别(89.5%vs.89.1%,8.0%vs.18.2%,P>0.05),而≥12枚淋巴结的Ⅱ期和Ⅲ期5年生存率明显高于<12枚(71.1%vs.32.6%,48.8%vs.30.0%,P<0.05),多因素COX回归模型分析表明,病检淋巴结数目是Ⅱ、Ⅲ期结直肠癌独立的预后因素.结论 病检的淋巴结数目主要通过影响Ⅱ、Ⅲ期的预后与结直肠癌总5年生存率明显相关,是Ⅱ、Ⅲ期结直肠癌独立的预后因素.

Abstract：

Objective To study the relationship between the number of examined lymph nodes and the prognosis of colorectal cancer by TNM stage. Methods According to the number of examined lymph nodes, 567 patients of colorectal carcinoma who underwent resection were divided into three groups: ≤ 6,7-11 and ≥ 12, the 5-year overall survival rates of three groups were compared. For each TNM stage ( stage Ⅰ -Ⅳ ) , patients were substratified into two groups basing on the number of examined lymph nodes:<12 group and ≥12 group, the 5-year survival rates of two groups in each TNM stage were assessed, and prognostic factors of stage Ⅱ and Ⅲ stage were analyzed. 5-year survival curves were estimated with the Kaplan-Meier method and compared by the log-rank test. Cox proportional models were used to conduct multivariate analyses of prognostic factors. Results The average number of examined lymph nodes was 16. 75 ±9. 88. With the patients grouped by the number of lymph nodes ( ≤6,7 -11 and ≥12 nodes) , the 5-year survival rate was 32. 3% , 43. 8% , and 57. 7% , the univariable analysis indicated that the 5-year survival rate of ≥ 12 examined nodes were significantly higher than the other groups (P<0. 05). There was no difference between two groups in the 5-year survival rates of stage Ⅰ or Ⅳ colorectal cancer (89. 5% vs.89. 1% ,8. 0% vs. 18. 2% , P>0. 05 ) , however, the 5-year survival rates of stage Ⅱ and Ⅲ colorectal cancer in ≥12 group were significantly higher than<12 group(71. 1% vs. 32. 6% ,48. 8% vs. 30. 0% ,P<0. 05) , multivariable analysis revealed that the number of lymph nodes examined was an independent factor of prognosis of stage Ⅱ and Ⅲ colorectal cancer. Conclusions The number of examined lymph nodes significantly influenced the 5-year overall survival rate of TNM stage Ⅱ and Ⅲ colorectal cancer.